Healthcare Capital Is Not Scarce. It Is Concentrated.
Roughly $1.55 billion moved into healthcare businesses in a single week in July, and the structures behind most of it are ones no independent practice has been shown.
Independent practice owners are told the capital market has closed to them. In the week ending July 13, 2026, roughly 1.55 billion dollars moved into healthcare businesses across three separate transactions, and not one of them stalled on a lender's inability to underwrite reimbursement risk. The capital is not scarce. It is concentrated in the hands of borrowers who had someone structuring the deal for them, and it is not reaching the practice that never had that person in the room.
One Week, Three Transactions
The largest was a take-private. A medical technology manufacturer focused on specialty nutrition and pain management devices agreed to go private at 25.00 dollars per share in cash, a premium of roughly 72 percent to its pre-announcement close, valuing the company at about 1.272 billion dollars in enterprise value. The buyer was an operationally oriented investor managing roughly 17.8 billion dollars.
The second was a recapitalization. A Colorado-based dental group received 170 million dollars in recapitalization financing from a syndicate of private credit and institutional lenders. No sale. The platform kept operating and the ownership structure held.
The third was a raise. A health technology company that helps providers manage risk for Medicare patients closed 110 million dollars: 50 million in equity and a 60 million dollar debt facility alongside it. The company was profitable in 2025, supports more than 10,000 providers across more than 40 states serving more than 250,000 beneficiaries, and manages roughly 3.6 billion dollars in annualized medical spend.
Three deals. One week. Roughly 1.55 billion dollars.
The Biggest Deal Was the One Where the Owners Left
Read the three in order of what the owner walked away with, not in order of size, and the ranking inverts. The 1.272 billion dollar transaction ends with the company privately held and the prior shareholders cashed out. The other two, roughly 280 million dollars combined, left ownership intact.
Debt did most of that work. Roughly 55 percent of the 110 million dollar raise, the 60 million dollar facility, was debt rather than equity, in a company profitable enough to service it. The entire 170 million dollar dental recapitalization was financing, not a sale. In both cases the operator got the capital and kept the business.
That is the pattern worth studying, because it is the pattern that is available to a practice with far less than 3.6 billion dollars of managed spend behind it. The structures scale down. What does not scale down automatically is the person who assembles them.
Why the Same Structure Never Reaches the Independent Group
On July 14, 2026, the Centers for Medicare and Medicaid Services proposed the calendar year 2027 Physician Fee Schedule, cutting the conversion factor for clinicians outside advanced alternative payment models to 32.84 dollars, down 1.68 percent, and to 33.17 dollars for qualifying participants, down 1.19 percent. A bank credit committee reads that headline as reimbursement risk and prices the whole sector accordingly, or declines it.
Meanwhile a health services deals report released in late June found that deal volume has softened this year while investors concentrate on assets with strong margin profiles, scalable operations, and measurable performance improvement. Capital did not leave healthcare. It got selective, and selectivity rewards whoever presents the collateral clearly.
So the independent group with 12 million dollars in revenue, 2.5 million dollars of receivables sitting in a 60 to 120 day reimbursement cycle, and 1.8 million dollars of imaging and clinical equipment on the books hears one answer from one bank, concludes the market has spoken, and takes the consolidator's call. The consolidator then finances the acquisition with the exact structures the practice was told it could not access.
How Thalos Capital Approaches This
The mechanism is not exotic. It is asset-based lending, working capital, and equipment financing built around collateral the practice already owns and a cash cycle that is predictable once someone maps it.
Thalos Capital starts by separating the practice's borrowing capacity from its P and L narrative. Receivables from commercial payers and Medicare remittances are a documented, recurring collection pattern, and they support advance rates once presented as such rather than as a reimbursement complaint. Equipment carries term capacity against useful life, which is where a 10 year imaging asset should be financed over 10 years and not funded out of the operating account. Where an ownership transition or partner buyout is the real question, strategic debt structures address it directly instead of routing it through a sale.
Thalos Capital then takes that structure to the sources that already underwrite healthcare-specific risk, on deals from 50 thousand to 100 million dollars and more across the United States and Canada. That is the same borrower-side work that produced the 170 million dollar recapitalization and the 60 million dollar facility, applied at the scale an independent group actually operates.
The cost of the wrong move here is not a rate spread. It is the difference between financing an expansion and selling the practice to fund it, and that decision is usually made on the belief that only one of the two was ever available. In the week just measured, roughly 280 million dollars of healthcare capital went to owners who kept their businesses. None of them found it by asking one bank.
Most financing situations have more options than the borrower initially sees. A conversation is enough to map them. Submit your financing request at https://thaloscapital.com/contact.
